CXCR2 and neoplasm: Another study revealed that tumor-derived chemokines such as IL-8 and CXCL5 drive the recruitment of MDSCs into patients with Enz-treated CRPC by binding to CXCR2, highlighting the blockade of CXCR2 as a potential strategy to increase Enz sensitivity 21,22.